Pharma BD Deal Intelligence
Mylan's $750M-800M Famy Care acquisition delivered a genuine women's health franchise—Yaz, Minastrin 24 Fe, Depo-Provera all launched from the deal—before Viatris wrote it off as non-core and sold it to Insud Pharma in 2024, eight years after close.
Headlined 'Mylan Inc. to Become a Women's Healthcare Powerhouse With $800 Million Buy'; notes Famy Care is the largest producer of generic oral contraceptives…
Bresch: 'In 2008, Mylan established a partnership with Famy Care, significantly enhancing its presence in the women's health care segment in the U.S. and other…
Mylan to acquire Famy Care women's health businesses for $750M cash plus up to $50M contingent payments, building vertically integrated platform with…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Mylan agreed to acquire certain women's healthcare businesses from Famy Care for $750M cash plus up to $50M contingent payments. Famy Care was the world's largest producer of generic OCPs. Acquisition closed November 20, 2015 via Mylan Laboratories Limited subsidiary.
Assessment window: 5yr post-close.
$19.8B Global contraceptives market 2015
Hormonal contraceptives (combined oral contraceptive pills, progestin-only pills, injectables, IUDs, hormone replacement therapy) prevent pregnancy by suppressing ovulation, thickening cervical mucus, or thinning the endometrium. Generic OCPs represent the highest-volume women's health category globally, with strong demand in emerging markets where access and affordability are primary purchase drivers. The category is highly commoditized, with competition driven by manufacturing scale, regulatory approvals, and supply reliability rather than innovation.
The Mylan-Famy Care transaction (announced February 2015, closed November 20, 2015 via Mylan Laboratories Limited subsidiary) consolidated the world's largest generic OCP manufacturer into a leading global generics platform. Famy Care's portfolio spanned oral and injectable contraceptives, IUDs, tubal rings, and HRT—with two of its four India-based facilities holding FDA and EU approvals. The competitive set in 2015 included Teva (post-Barr/Duramed legacy products like Plan B and Seasonique generics), Lupin (Tydemy authorized generics), Glenmark, Mayne Pharma, and Aurobindo, alongside branded incumbents Bayer (Yaz/Yasmin), Allergan (Lo Loestrin), and Merck (NuvaRing). The Famy assets gave Mylan vertical integration, accelerated entry into emerging markets, and an established US/EU-quality manufacturing footprint—building on existing supply partnerships in North America, Europe, and Australia. The acquired entity was rebranded Jai Pharma. The strategic logic was scale-driven: capturing pricing leverage in a commoditized category by becoming the unambiguous global volume leader.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan Inc. / Famy Care Limited (women's healthcare businesses) (this deal) | 2015 | $800M | 56 |
| Mylan Inc. / Theravance Biopharma, Inc. (TD-4208 program) | 2015 | $265M | 61 |
| Mylan Inc. / Bioniche Pharma Holdings Limited | 2010 | $550M | 60 |
| Mylan Inc. / Agila Specialties (Strides Arcolab) | 2013 | $1.8B | 45 |
| Mylan Inc. / Abbott Laboratories (non-U.S. developed-markets specialty and branded generics business) | 2014 | $5.3B | 33 |
| Sumitovant Biopharma / Myovant Sciences Ltd. | 2022 | $1.7B | 60 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
← Browse all deals · How we score deals
More: 2015 deals · Mylan Inc. deals · Women's Health deals